Back grey_arrow_rt.gif
 
 
Festinavir (OBP-601): new NRTI Licensed for Development by BMS
 
 
  from Jules: this is a unique situation, a new HIV drug being developed!
 
"Festinavir (Fig. 1) is a novel NRTI (derivative of d4T) with potent in vitro anti-HIV activity against several wild type HIV-1 subtypes and multidrug resistant (MDR) clinical isolates, including TAM, NAMs, tenofovir and abacavir resistant virus mutation strains. It is less inhibitory to mitochondrial DNA synthesis and its anti-HIV activity persists longer than other thymidine analogs after drug removal.......Festinavir was generally well tolerated up to 900mg administered as single doses. There were no serious adverse events and no discontinuations due to adverse events. All treatment-emergent adverse events (AEs) by subject and system organ class were presented in Table 4. All adverse events were transient and mild to moderate in intensity.... The potent anti-HIV activity and susceptibility of MDR HIV-1 isolates coupled with its safety and tolerability in the current study support further evaluation of OBP-601 in HIV-infected individuals. A dose of >100 mg daily is expected to provide Cmin levels adequate to suppress subtype HIV-1 isolates with or without M184V mutation."
 
A Single-dose Escalation Study to Evaluate the Safety ...
Background: OBP-601 is a novel NRTI (derivative of stavudine, d4T) with potent in vitro anti-HIV activity against several wild type HIV-1 subtypes and ... www.natap.org/2009/CROI/croi_85.htm
 
A Phase-Ib/IIa dose-escalation study for evaluation of the safety ...
Background: OBP-601 is a novel NRTI with in vitro activity against several wild type and ... OBP-601 is a weak inhibitor of mitochondrial DNA synthesis. ... www.natap.org/2010/ICAAC/ICAAC_53.htm

 
 
 
 
  icon paper stack View Older Articles   Back to Top   www.natap.org